MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial
Wednesday, October 14, 2009 14:00 IST Martinsried, Munich
MediGene AG has successfully completed patient recruitment into its randomized phase-II trial of EndoTAG-1 for the treatment of triple receptor-negative breast cancer.